Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases (2010)

  • Authors:
  • USP affiliated authors: BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
  • USP Schools: FM
  • DOI: 10.1007/s12016-009-8140-3
  • Subjects: AUTOIMUNIDADE; PROGNÓSTICO; IMUNOGENÉTICA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s12016-009-8140-3 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Clinical Reviews in Allergy and Immunology

    ISSN: 1080-0549

    Citescore - 2017: 5.02

    SJR - 2017: 0.967

    SNIP - 2017: 1.577


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM1834009-10BCSEP 067 2010
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      AIKAWA, Nádia Emi; CARVALHO, Jozélio Freire de; SILVA, Clovis Artur Almeida; BONFÁ, Eloísa Silva Dutra de Oliveira. Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases. Clinical Reviews in Allergy & Immunology, Totowa, v. 38, n. 2, p. 82-89, 2010. Disponível em: < http://www.springerlink.com/content/k20181608v6n6330/fulltext.pdf > DOI: 10.1007/s12016-009-8140-3.
    • APA

      Aikawa, N. E., Carvalho, J. F. de, Silva, C. A. A., & Bonfá, E. S. D. de O. (2010). Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases. Clinical Reviews in Allergy & Immunology, 38( 2), 82-89. doi:10.1007/s12016-009-8140-3
    • NLM

      Aikawa NE, Carvalho JF de, Silva CAA, Bonfá ESD de O. Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases [Internet]. Clinical Reviews in Allergy & Immunology. 2010 ; 38( 2): 82-89.Available from: http://www.springerlink.com/content/k20181608v6n6330/fulltext.pdf
    • Vancouver

      Aikawa NE, Carvalho JF de, Silva CAA, Bonfá ESD de O. Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases [Internet]. Clinical Reviews in Allergy & Immunology. 2010 ; 38( 2): 82-89.Available from: http://www.springerlink.com/content/k20181608v6n6330/fulltext.pdf

    Referências citadas na obra
    Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602
    Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411
    Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45
    van der Laken CJ, Voskuyl AE, Roos JC et al (2007) Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66:253–256
    Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274–280
    Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524–528
    Abe T, Takeuchi T (2001) Rheumatoid arthritis and tumor necrosis factor alpha. Autoimmunity 34:291–303
    Miele E, Markowitz JE, Mamula P, Baldassano RN (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38:502–508
    Sidiropoulos PI, Boumpas DT (2006) Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65:701–703
    Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34:19–22
    Haraoui B, Cameron L, Ouellet M, White B (2006) Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 33:31–36
    Dore RK, Mathews S, Schechtman J et al (2007) The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25:40–46
    van de Putte LB, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516
    Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346–357
    Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M (2007) Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 7:35–41
    Elkayam O, Burke M, Vardinon N et al (2005) Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38:155–160
    Atzeni F, Doria A, Ghirardello A et al (2008) Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 41:87–91
    Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:72–79
    Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563
    Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56:1226–1231
    Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608
    Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2:542–553
    Radstake TR, Svenson M, Eijsbouts AM et al (2008) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis, Nov 19. [Epub ahead of print]
    Ebert EC, Das KM, Mehta V, Rezac C (2008) Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol 154:325–331
    de Vries MK, Wolbink GJ, Stapel SO et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66:1252–1254
    Wolbink GJ, Vis M, Lems W et al (2006) Development of anti infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711–715
    Aybay C, Ozel S, Aybay C (2006) Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 26:473–480
    Svenson M, Geborek P, Saxne T, Bendtzen K (2007) Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46:1828–1834
    van der Bijl AE, Breedveld FC, Antoni CE et al (2008) An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27:1021–1028
    van den Bemt BJ, den Broeder AA, Snijders GF et al (2008) Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 67:1697–1701
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T (2006) Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54:3782–3789
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035
    Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124:917–924
    Denton CP, Engelhart M, Tvede N et al (2008) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis, Sep 9. [Epub ahead of print]
    Langley RG, Gordon KB (2007) Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 6:1205–1212
    Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31:1538–1545
    Ainsworth MA, Bendtzen K, Brynskov J (2008) Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol 103:944–948
    Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777
    Keystone EC, Schiff MH, Kremer JM et al (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353–363
    Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769
    de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (AS). Ann Rheum Dis 68:531–535
    Tyring S, Gordon KB, Poulin Y et al (2007) Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143:719–726
    Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, Heilig B (2007) Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269–274
    Bartelds GM, Wijbrandts CA, Nurmohamed MT et al (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921–926
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG (2007) Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 56:1232–1239